Boehringer Ingelheim Joins EHDEN

Brussels, Belgium, 27 July 2021: EHDEN is delighted to announce that Boehringer Ingelheim has today become a Partner of the EHDEN Consortium.  They now join the 11 Public Partners, and 11 Industry Partners, adding their expertise, resources, and support in creating an ecosystem for working with real-world data across the European region via a federated network.

To date, EHDEN has selected 98 Data Partners in 22 countries with > 400 million records to collaborate within an international network, supported by 49 selected small-to-medium-sized enterprises in 20 countries for data harmonisation to the OMOP common data model. The project is already generating evidence of real-world experience in multiple diseases, including in COVID-19, and also launched an open and free educational Academy that has had more than 1,300 enrollees worldwide in its first year.

Boehringer Ingelheim will work with project colleagues on technical aspects, research, and evidence generation, and developing the sustainability of the project.

Laura Wallace, Head of the Global Epidemiology and Real World Evidence Center of Excellence, Boehringer Ingelheim, said “Joining the EHDEN consortium IMI2 BD4BO project extends our journey in the ability to work with real world data beyond the traditional data assets currently available broadening our ability to study populations in all corners of Europe.  The research of the consortium allows us to reach our ultimate goal of bringing the best treatments and healthcare solutions to our patients across Europe and the globe.”

Nigel Hughes, EHDEN EFPIA Project Lead and Scientific Director, Epidemiology, Janssen R&D, said, “Boehringer Ingelheim’s decision to join us on our journey is an excellent endorsement of the EHDEN project. Their expertise in working with real-world data, OMOP and standardised tools and methods to generate real-world evidence strengthens the Consortium and network collaboration. We very much look forward to their contribution in creating a new research infrastructure in Europe to meet the needs of 21st century healthcare and innovation.”



Every day, patients are not receiving optimal healthcare because we are not able to tap into the unlimited potential of real-world data. In response to this, EHDEN (European Health Data and Evidence Network) was created as a public-private partnership under the framework of the IMI2 (Innovative Medicines Initiative). EHDEN aspires to be the trusted observational research ecosystem to enable better health decisions, outcomes, and care, with a mission to provide a new paradigm for the discovery and analysis of health data in Europe, by building a large-scale, federated network of data sources standardized to a common data model.

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Learn more at

The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.